Pancreatic Cancer Research

ResearcherNortheastern UniversityActive in the last 2 years

Si Young Song

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1417-4314; OpenAlex author ID A5035695627. Sources: OpenAlex.

Their work

Papers
68 (first author 2, last author 23)
Trials
0
Grants
0
Labs led
1
Collaborators
96
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 7 papers · 2014: 11 papers · 2015: 1 paper · 2016: 7 papers · 2017: 8 papers · 2018: 3 papers · 2019: 3 papers · 2020: 6 papers · 2021: 5 papers · 2022: 5 papers · 2023: 3 papers · 2024: 3 papers

Papers 50 of 68

  1. Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin leve… Last author DOI 10.1038/s41416-023-02474-w↗
  2. Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum … Last author DOI 10.1038/s41416-023-02520-7↗
  3. Integrative analysis of spatial and single-cell transcriptome data from human pancreatic cancer reveals an intermediate cancer cell population associated with … Co-author DOI 10.1186/s13073-024-01287-7↗
  4. Copula graphic estimation of the survival function with dependent censoring and its application to analysis of pancreatic cancer clinical trial. Co-author DOI 10.1177/09622802231158812↗
  5. Difference of Risk of Pancreatic Cancer in New-Onset Diabetes and Long-standing Diabetes: A Population-based Cohort Study. Co-author DOI 10.1210/clinem/dgac728↗
  6. Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients with pancreatic cancer: a prospective stud… Last author DOI 10.3389/fonc.2023.1206565↗
  7. A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma. Last author DOI 10.1002/ijc.34144↗
  8. BRCA 1/2 Germline Mutation Predicts the Treatment Response of FOLFIRINOX with Pancreatic Ductal Adenocarcinoma in Korean Patients. Co-author DOI 10.3390/cancers14010236↗
  9. Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. Co-author DOI 10.3390/cancers14051244↗
  10. Evaluation of the 8th Edition AJCC Staging System for the Clinical Staging of Pancreatic Cancer. Co-author DOI 10.3390/cancers14194672↗
  11. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. Co-author DOI 10.5009/gnl20301↗
  12. Profiling of conditionally reprogrammed cell lines for in vitro chemotherapy response prediction of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103218↗
  13. Peripheral natural killer cell activity is associated with poor clinical outcomes in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jgh.15265↗
  14. GLRX3, a novel cancer stem cell-related secretory biomarker of pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12885-021-08898-y↗
  15. Usefulness of Smartphone Apps for Improving Nutritional Status of Pancreatic Cancer Patients: Randomized Controlled Trial. Co-author DOI 10.2196/21088↗
  16. Identification of Circulating Serum miRNAs as Novel Biomarkers in Pancreatic Cancer Using a Penalized Algorithm. Last author DOI 10.3390/ijms22031007↗
  17. Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer. Co-author DOI 10.1007/s00280-020-04051-x↗
  18. Radiographic portal or superior mesenteric vein invasion is an independent prognostic factor in non-metastatic pancreatic ductal adenocarcinoma: A missing bloc… Co-author DOI 10.1016/j.pan.2020.05.017↗
  19. Lewis Antigen Phenotype and Survival of Patients With Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001687↗
  20. Preoperative prediction of futile surgery in patients with radiologically resectable or borderline resectable pancreatic adenocarcinoma. Co-author DOI 10.1111/jgh.14837↗
  21. FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study. Co-author DOI 10.4251/wjgo.v12.i2.182↗
  22. Analysis of Clinical Predictive Factors Affecting the Outcome of Second-Line Chemotherapy for Gemcitabine-Refractory Advanced Pancreatic Cancer. Co-author DOI 10.5009/gnl18419↗
  23. Establishment of pancreatic cancer cell lines with endoscopic ultrasound-guided biopsy via conditionally reprogrammed cell culture. Co-author DOI 10.1002/cam4.2210↗
  24. Skeletal Muscle Mass Predicts Poor Prognosis in Patients with Advanced Pancreatic Cancer Undergoing Second-Line FOLFIRINOX Chemotherapy. Last author DOI 10.1080/01635581.2019.1597906↗
  25. Plasma Chromogranin A as a Prognostic Marker in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000001319↗
  26. Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer. Last author DOI 10.1038/s41598-018-21823-x↗
  27. Pancreatic-cancer-cell-derived trefoil factor 2 impairs maturation and migration of human monocyte-derived dendritic cells in vitro. Co-author DOI 10.1080/19768354.2018.1527721↗
  28. Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. Co-author DOI 10.4251/wjgo.v10.i11.421↗
  29. The DNA aptamer binds stemness-enriched cancer cells in pancreatic cancer. Last author DOI 10.1002/jmr.2591↗
  30. A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance. Last author DOI 10.1038/srep41615↗
  31. Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A sing… Co-author DOI 10.1053/j.seminoncol.2018.01.001↗
  32. The Significance of the Prognostic Nutritional Index for All Stages of Pancreatic Cancer. Co-author DOI 10.1080/01635581.2016.1250921↗
  33. A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreati… Last author DOI 10.1097/md.0000000000005702↗
  34. Clinical characteristics of second primary pancreatic cancer. Co-author DOI 10.1371/journal.pone.0179784↗
  35. Suppression of pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer to gemcitabine and 5FU, and inhibits the form… Last author DOI 10.18632/oncotarget.19458↗
  36. Assessment of the Risk of Colorectal Cancer Survivors Developing a Second Primary Pancreatic Cancer. Co-author DOI 10.5009/gnl16526↗
  37. Embigin is overexpressed in pancreatic ductal adenocarcinoma and regulates cell motility through epithelial to mesenchymal transition via the TGF-β pathway. Last author DOI 10.1002/mc.22309↗
  38. Can metformin change the prognosis of pancreatic cancer? Retrospective study for pancreatic cancer patients with pre-existing diabetes mellitus type 2. Co-author DOI 10.1016/j.dld.2015.12.006↗
  39. Visceral Obesity is Associated with Poor Prognosis in Pancreatic Adenocarcinoma. Co-author DOI 10.1080/01635581.2016.1134600↗
  40. Statin Use and Its Impact on Survival in Pancreatic Cancer Patients. Co-author DOI 10.1097/md.0000000000003607↗
  41. Risk Factors Associated with Loco-Regional Failure after Surgical Resection in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1371/journal.pone.0157196↗
  42. Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer. Co-author DOI 10.3349/ymj.2016.57.5.1124↗
  43. A Comparison of Gastrointestinal Toxicities between Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy for Pancreatic Cancer. Last author DOI 10.5009/gnl15186↗
  44. Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles. Co-author DOI 10.1097/md.0000000000002168↗
  45. Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer. Last author DOI 10.1007/s00262-014-1566-3↗
  46. Clinical usefulness of ¹⁸F-fluorodeoxyglucose-positron emission tomography in patients with locally advanced pancreatic cancer planned to undergo concurrent ch… Co-author DOI 10.1016/j.ijrobp.2014.05.030↗
  47. Notch pathway activation is associated with pancreatic cancer treatment failure. First author DOI 10.1016/j.pan.2013.11.011↗
  48. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma. Co-author DOI 10.1021/pr5002719↗
  49. Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea. Last author DOI 10.1097/mpa.0000000000000163↗
  50. Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanc… Co-author DOI 10.1159/000375402↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jeong Youp Park · 45 shared papers, 2011–2024 · strength 3.84
  2. Moon Jae Chung · 43 shared papers, 2013–2024 · strength 3.84
  3. Seungmin Bang · 42 shared papers, 2011–2024 · strength 3.73
  4. Seung Woo Park · 42 shared papers, 2011–2024 · strength 3.70
  5. Hee Seung Lee · 32 shared papers, 2016–2024 · strength 3.44
  6. Jung Hyun Jo · 24 shared papers, 2014–2024 · strength 3.03
  7. Huapyong Kang · 11 shared papers, 2014–2022 · strength 1.02
  8. Mi‐Suk Park · 7 shared papers, 2017–2024 · strength 0.88
  9. Jiyoung Keum · 5 shared papers, 2020–2023 · strength 0.69
  10. Dawoon Jung · 6 shared papers, 2016–2023 · strength 0.68
  11. Jae Bock Chung · 13 shared papers, 2012–2017 · strength 0.68
  12. Ho Kyoung Hwang · 8 shared papers, 2012–2024 · strength 0.68
  13. Chang Moo Kang · 11 shared papers, 2012–2022 · strength 0.67
  14. Woo Jung Lee · 11 shared papers, 2012–2022 · strength 0.60
  15. Hyungsik Roger Moon · 3 shared papers, 2023–2024 · strength 0.55
  16. Seung‐seob Kim · 3 shared papers, 2020–2022 · strength 0.38
  17. Dong Uk Kim · 3 shared papers, 2017–2024 · strength 0.38
  18. Ho Gak Kim · 3 shared papers, 2017–2024 · strength 0.38
  19. Ho Soon Choi · 3 shared papers, 2017–2024 · strength 0.38
  20. Yong‐Tae Kim · 3 shared papers, 2017–2024 · strength 0.38
  21. In Rae Cho · 5 shared papers, 2013–2021 · strength 0.37
  22. Chang‐Hwan Park · 2 shared papers, 2024 · strength 0.33
  23. Jae Woo Kim · 2 shared papers, 2024 · strength 0.33
  24. Eui Joo Kim · 2 shared papers, 2024 · strength 0.33
  25. Hong Sik Lee · 2 shared papers, 2024 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.